Significant Agreements - Neurocrine Collaboration receivables and contract liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Related party collaboration receivables, beginning balance	$ 3,341
Related party collaboration receivables, ending balance	676	$ 3,341
Deductions	0	0	$ (40,000)
2023 Neurocrine Collaborative Agreement and 2019 Neurocrine Collaborative Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Related party collaboration receivables, beginning balance	3,341
Additions		12,269
Deductions		(14,934)
Related party collaboration receivables, ending balance	676	3,341
Deferred revenue, beginning balance	75,240
Additions		1,592
Deductions		(46,435)
Deferred revenue, ending balance	30,397	$ 75,240
Discovery program 3 | Neurocrine | 2023 Neurocrine Collaborative Agreement and 2019 Neurocrine Collaborative Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Additions	1,600
Deductions	$ 46,400